INS and Insulin resistance: Its primary pharmacodynamic action is believed to involve activation of the AMP-activated protein kinase (AMPK) pathway, which enhances insulin sensitivity and improves peripheral insulin resistance in patients with T2DM—an axis potentially critical to maintaining cerebral glucose homeostasis.